A menopause appointment can begin with a symptom but end with more than one medicine. That makes the explanation of each part important. Defy Medical publishes a menopause care service with consultation and follow-up, while its broader hormone pages describe several treatment forms. Those pages do not establish which progesterone preparation a particular reader would receive.

We reviewed Defy’s primary service and price information on September 29, 2026. This review asks what a consultation would need to clarify about treatment purpose, existing hormone exposure and relevant history. It does not assess an individual prescription or demonstrate that Defy uses a particular uterus-history questionnaire. A publicly advertised care pathway cannot answer those personal clinical questions.

Editorial illustration: two consultation chairs and a notebook on a side table.
Defy Medical menopause review: the purpose of each part of a hormone plan — bring the unanswered questions into the appropriate professional conversation.

A symptom list does not assign every medicine a role

The menopause service offers an extended consultation and continuing care rather than simply selling an identified capsule. Its usefulness for this question is the opportunity to ask why a proposed medicine belongs in the plan. Relief of a bothersome symptom and protection of the uterine lining are different treatment aims; a reader should not have to infer which one is intended from the number of medicines listed. The systemic estrogen guide explains that distinction. The public service description does not show a completed assessment, a prescribed combination or a promised result for someone booking today.

Editorial illustration: two consultation chairs and a notebook on a side table.
A symptom list does not assign every medicine a role — bring the unanswered questions into the appropriate professional conversation.

The hormone menu leaves the exposure question open

Defy’s wider hormone-therapy menu includes different hormones and delivery forms. A reference to oral hormone capsules does not identify a specific progesterone manufacturer or establish that every patient receives an oral product. It also does not tell us whether a reader’s existing estrogen is intended to act systemically or locally. ACOG’s patient guidance distinguishes those kinds of estrogen treatment. In an actual discussion, the current medicine name and route would make the question more precise than “I use hormones.” The BodyLogicMD review considers a different service whose testing language similarly needs a stated clinical objective.

An operation name needs a more complete account

A previous hysterectomy is relevant information, but that word alone is not a complete surgical record. ACOG describes total and supracervical hysterectomy separately and distinguishes removal of the ovaries from removal of the uterus. This review cannot reconstruct an operation from a short history or use it to decide whether progesterone belongs in a plan. Nor does Defy’s general service page establish how such records are requested or reviewed. Our questions after hysterectomy provide context for asking the clinician what information is missing and how the documented history affects the proposed treatment goal.

Editorial illustration: an unbranded container, information sheet and magnifying glass.
An operation name needs a more complete account — keep the exact product identity and its complete label together.

A local treatment question should stay specific

The phrase estrogen therapy covers more than one clinical situation. The 2020 NAMS consensus abstract states that a progestogen is not indicated with low-dose vaginal estrogen, while also noting that endometrial safety was not studied in clinical trials beyond one year. That qualified statement is not permission to classify an unidentified product or change a prescription. It explains why a consultation should identify the preparation and intended exposure before applying a general rule. The local vaginal estrogen discussion keeps this separate from systemic treatment. Defy’s broad menu does not settle the classification for an individual reader.

A monthly average is not a care commitment

Defy’s BHRT cost explanation describes averages below $200 per month in the first year and below $150 thereafter, including consultations, laboratory work and medication. It says patients pay for items as needed rather than through a monthly subscription. These figures therefore do not promise a fixed monthly invoice, a particular progesterone supply or a set number of reassessments. A useful estimate would identify the consultation, proposed tests, dispensing charges and later visits separately. Changing the clinical plan could change the bill. The average should not be used to decide that a follow-up assessment has already been purchased. A projected annual pattern also cannot show when a particular charge will fall due. The written estimate should make any required follow-up and its separate cost visible before the reader treats a lower later-year average as evidence of less clinical work.

Editorial illustration: an unbranded container, information sheet and magnifying glass.
A monthly average is not a care commitment — keep the exact product identity and its complete label together.

Follow-up needs a clinical owner and a route

Defy advertises ongoing follow-up, but the public description does not establish a personal response deadline or the arrangements for investigating a new symptom locally. That matters when an online discussion needs an examination or another clinician’s records. NHS patient guidance advises having postmenopausal vaginal bleeding checked even if it happens only once or involves a small amount. This review cannot attribute bleeding to a medicine or advise waiting for a routine renewal. The unexpected bleeding guide focuses on professional assessment. UK referral arrangements should not be assumed to apply to Defy’s US service.

The useful outcome is an explanation, not a longer list

Before comparing services, it helps to distinguish the questions answered by Defy’s consultation offer from those still requiring clinical judgment. The service is documented; the exact preparation, reason for adding it, place of dispensing, location eligibility and responsibility for reassessment remain individual matters. Myla Health provides a contrasting UK example with published communication and follow-up arrangements, not an interchangeable route for US patients. A meaningful comparison asks whether the eventual explanation connects each medicine to a goal and a review point. Neither a long hormone menu nor a low average price supplies that explanation by itself.

Sources behind this article

Use the original documents to check their scope. A provider’s offer and a named medicine’s label establish different facts.

  1. Defy Medical: Menopause careProvider menopause consultation and follow-up offer; no confirmed individual medicine, outcome or availability · Checked 2026-09-29
  2. Defy Medical: Hormone therapyProvider treatment and route menu; oral hormone capsules do not establish a named progesterone formulation · Checked 2026-09-29
  3. ACOG: Hormone Therapy for MenopauseUS professional patient guidance, last updated October 2021 and reviewed February 2024; treatment categories and reassessment, not individual prescribing or a provider protocol · Checked 2026-09-29
  4. ACOG: HysterectomyUS professional patient guidance, updated September 2024 and reviewed May 2025; distinguishes operative terms without inferring an individual operation or hormone need · Checked 2026-09-29
  5. NAMS: The 2020 genitourinary syndrome of menopause position statement — abstractPublished professional consensus abstract only; low-dose vaginal estrogen distinction retains absent endometrial-safety clinical trials beyond one year, not a complete-paper or individualized assessment · Checked 2026-09-29
  6. Defy Medical: How much does BHRT cost?Provider illustrative monthly cost averages, not fixed monthly billing or a capsule quote · Checked 2026-09-29
  7. NHS: Postmenopausal bleedingUK public patient guidance, reviewed September 24, 2026; bleeding assessment advice does not diagnose a cause or transfer NHS referral timings to US services · Checked 2026-09-29
Read our editorial method →